The American Society of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) released Practice Bulletin 226, “Screening for Fetal Chromosomal Abnormalities,” in October 2020, advocating that all pregnancies be screened with NIPT. This guideline endorses NIPT as the most sensitive and specific prenatal screening option versus traditional screening methods.
"Cell-free DNA screening [NIPT] […] should be discussed and offered to all patients early in pregnancy regardless of maternal age or baseline risk."
"Cell-free DNA [NIPT] is the most sensitive and specific screening test for the common fetal aneuploidies (trisomies 21, 13, and 18) and can be performed at any time after 9-10 weeks of gestation."
—ACOG/SMFM clinical management guidelines for obstetricians and gynecologists
These pages are intended for healthcare professional audiences. Some solutions referenced in this content may not be available or approved in specific geographies.